<DOC>
	<DOCNO>NCT01397734</DOCNO>
	<brief_summary>In research study , investigator look see whether combination arsenic trioxide tyrosine kinase inhibitor safe , effect chronic myelogenous leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Tyrosine Kinase Inhibitors Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Participants must diagnosis chronic myelogenous leukemia confirm fluorescent In Situ Hybridization ( FISH ) BCR/ABL translocation and/or standard cytogenetics analysis . Participants may receive prior hydroxyurea may currently treat hydroxyurea time study initiation . Participants may receive prior TKI therapy , however must stable dose current TKI least one month prior enrollment . Participants must demonstrate evidence persistent disease either cytogenetics/FISH PCR BCR/ABL peripheral blood bone marrow . Greater equal 18 year age . Because little dosing adverse event data currently available use Arsenic participant &lt; 18 year age , child exclude study . Life expectancy great 3 month ECOG performance status &lt; 2 Participants must normal organ marrow function define : Bilirubin ≤ 2.0 mg/dL Creatinine ≤ 2 mg/dL ALT &lt; 2.5 X institutional upper limit normal AST &lt; 2.5 X institutional upper limit normal WBC &gt; 2.0 K/uL Platelets &gt; 100K Oxygen saturation &gt; 95 % room air The effect Arsenic develop human fetus unknown . For reason , woman childbearing potential must document negative pregnancy test ; addition , agreement use adequate contraception ( hormonal barrier method birth control ; abstinence ) must document woman childbearing potential men prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately All patient must demonstrate ability understand investigational nature study must sign write informed consent document accordance institutional federal guideline History acute myocardial infarction , unstable angina , congestive heart failure , arrhythmia within last three month Participants may receive study agent Mean QTc &gt; 450 ms time screen Use potassium waste diuretic study treatment Patients take drug generally accept risk cause Torsades de Pointes . The following must discontinue least 7 day prior enrollment eligible : quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide , erythromycins , clarithromycin , chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Drugs highly dependent CYP3A4 metabolism narrow therapeutic index ( see Appendix A ) allow must use caution Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Concurrent uncontrolled psychiatric medical condition may interfere study completion . Pregnant woman exclude study risk Arsenic develop fetus unknown . Because unknown potential risk adverse event nurse infant secondary treatment mother Arsenic , breastfeed discontinue mother treated clinical trial Individuals history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin HIVpositive individual combination antiretroviral therapy ineligible potential pharmacokinetic interaction TKI therapy Arsenic . In addition , individual increase risk lethal infection treat marrowsuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>Chronic Myeloid leukemia</keyword>
	<keyword>Arsenic</keyword>
	<keyword>Arsenic trioxide</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>TKI</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
</DOC>